Search | Clinical Trials Finder

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Dapagliflozin placebo, Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 38
States / cities: Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more

Conditions: Rheumatoid Arthritis
Interventions: Secukinumab (AIN457), Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 25
States / cities: Peoria, Arizona • Santa Monica, California • Upland, California + 20 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Anaheim, California • Fountain Valley, California + 19 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Litchfield Park, Arizona • Phoenix, Arizona • Tempe, Arizona + 23 more

Conditions: Major Depressive Disorder, Primary Hypersomnia, Bipolar Disorder, Narcolepsy, Primary Insomnia
Interventions: Acoustical slow wave induction; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 60 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Sleep, Obesity
Interventions: Increase Sleep, Decrease Sleep; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 8 Years to 11 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Gastrointestinal Neoplasms
Interventions: Education/Daily Planning; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Placebo matching Saxagliptin, Metformin, Placebo matching Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 83
States / cities: Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 80 more

Conditions: Ulcerative Colitis
Interventions: Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more

Conditions: Rheumatoid Arthritis
Interventions: AIN457, Placebo, Abatacept; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Anniston, Alabama • Vestavia Hills, Alabama • Freemont, California + 40 more

Conditions: Opioid Use Disorder
Interventions: SUN, SUN + Telebridge, ED-ITT, ED-ITT + BHS; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Colton, California

Conditions: Type 2 Diabetes
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 41
States / cities: Sheffield, Alabama • Surprise, Arizona • Tucson, Arizona + 36 more

Conditions: Generalized Anxiety Disorder
Interventions: Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 36
States / cities: Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more

Conditions: Child Abuse, Intimate Partner Violence, Secondary Prevention, Parenting
Interventions: Pregnant Moms' Empowerment Program, Reminiscing and Emotion Training, Pregnancy - Active Control, Enhanced Case Management; Behavioral
Lead sponsor: University of Notre Dame; Other
Eligibility: 3 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Notre Dame, Indiana • Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin XR, Metformin IR, Placebo matching with Metformin XR, Placebo matching with Metformin IR; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 29 more

Conditions: Healthy Lifestyle, Home Environment Related Disease, Cognitive Change, Child Behavior, Child Obesity, Parenting, Parents, Parent-Child Relations
Interventions: HomeStyles-2: Obesity Prevention Program for Families with Children in Middle Childhood; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 24 Years to 50 Years
Enrollment: 459 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 49
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions: continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp; Device · Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 40 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Back Pain Lower Back Chronic, Chronic Pain
Interventions: Buprenorphine Buccal Film [Belbuca], Urine Drug Screening, actigraph, PROMIS 29, sit to stand test, numerical rating scale pain score, patient global impression of function, PROMIS - sleep; Drug · Other · Device + 1 more
Lead sponsor: Carolinas Pain Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Viral Infections After HSCT
Interventions: VSTs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 4 Weeks to 45 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Suicide
Interventions: Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Dialectical Behavior Therapy (DBT) - Phase 2, Maintenance/Monitoring - Phase 2, Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Reno, Nevada • New Brunswick, New Jersey • Durham, North Carolina + 1 more

Conditions: Pediatric Obesity
Interventions: Topiramate, Phentermine; Drug
Lead sponsor: Janey Pratt; Other
Eligibility: 12 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes

Neurophysiologic Correlates of Hypersomnia

Effects of Sleep Duration on Eating and Activity Behaviors

Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients

Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

The Unique and Combined Effects of Prenatal and Early Childhood Programming on Child Maltreatment: Examining Mechanisms of Change

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

True Functional Restoration and Analgesia in Non-Radicular Low Back Pain

Allogeneic Virus-specific T Cell Lines (VSTs)

Comprehensive Adaptive Multisite Prevention of University Student Suicide

Medications After Adolescent Bariatric Surgery